Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 10/20 | 0.36 |
| ▸ | VDR | P11473 | 7/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9934954 | 1.00 | CYP1A2 (0.42) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL9933992 | 1.00 | CYP1A2 (0.42) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL9935590 | 0.83 | APP (0.31) | VDR | |
| SCHEMBL9935217 | 0.80 | CYP1A2 (0.41) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL12004064 | 0.75 | CYP1A2 (0.41) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL9933753 | 0.72 | SLC29A1 (0.40) | KMT2A | |
| SCHEMBL13187502 | 0.70 | CYP1A2 (0.46) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL16785511 | 0.70 | CYP1A2 (0.46) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL22341974 | 0.69 | CYP1A2 (0.41) | CYP1A2KDM4EAGTR1LMNATSHR | |
| SCHEMBL9934908 | 0.69 | IKBKB (0.31) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8476287-B2 | 3-hydroxy-5-arylisothiazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-07-02 | — | — | US | disclosed |
| US-8455500-B2 | 3-hydroxy-5-arylisoxazole derivative | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2013-06-04 | — | — | US | disclosed |
| EP-2518060-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-10-31 | — | — | EP | disclosed |
| EP-2495238-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | Mochida Pharmaceutical Co., Ltd. (JP) | 2012-09-05 | — | — | EP | disclosed |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-08-30 | — | — | US | disclosed |
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | MOCHIDA PHARMACEUTICAL CO., LTD. (JP) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157459-A1 | NOVEL 3-HYDROXY-5-ARYLISOTHIAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | CYP1A2 3016/4885KDM4E 2641/4885AGTR1 135/4885 |
| US-20120220772-A1 | NOVEL 3-HYDROXY-5-ARYLISOXAZOLE DERIVATIVE | GPR119, GPR27, NR0B1 | CYP1A2 2356/4885KDM4E 2811/4885AGTR1 157/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.